Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesNeurology/NeurosurgeryCapital Bluecross Aduhelm Coverage/Prior Auth | Op…
    Ask Trek AI about this page
    CurrentCapital BluecrossPolicy IC-0610NC

    Aduhelm (aducanumab-avwa) (Intravenous) Coverage Criteria

    Customize your policy alerts

    Sign up for Capital Bluecross Policy IC-0610NC alerts

    Get alerted when Policy IC-0610NC changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs coverage and prior authorization for Aduhelm (aducanumab-avwa) intravenous treatment and states the payer's stance on its medical necessity for Alzheimer's disease and related indications.

    Policy Summary
    PayerCapital Bluecross
    PolicyAduhelm (aducanumab-avwa) (Intravenous) Coverage Criteria
    Policy CodePolicy IC-0610NC
    Change TypeNo material change
    Effective Date
    Last ReviewJun 1, 2023
    Next Review DateJun 1, 2023
    Key ActionObtain prior authorization for Aduhelm (aducanumab-avwa) before billing.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    investigationalcoverage stance
    J0172HCPCS code
    G30.*, G31.84ICD-10 examples
    accelerated 06/07/2021FDA pathway

    Coverage Determination

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Investigational — All Indications

    Not covered / investigational

    Investigational for all indications: Aduhelm (aducanumab-avwa) is considered investigational for all indications including, but not limited to, treatment of Alzheimer's Disease (AD), cognitive impairment due to AD, and AD dementia.

    Insufficient clinical evidence for demonstrated efficacy.

    Aduhelm (aducanumab-avwa) is not covered. This policy designates Aduhelm as investigational for all indications, including, but not limited to, treatment of Alzheimer's disease (AD), cognitive impairment due to AD, and AD dementia.

    The rationale for the investigational designation is that there is insufficient clinical evidence demonstrating efficacy of Aduhelm for the treatment of Alzheimer's disease or related cognitive impairments.

    Billing and Diagnosis Codes

    Billing HCPCS CodeHCPCS
    J0172Injection, aducanumab-avwa, 2 mg; 1 billable unit = 2 mg
    NDCsNDC
    64406-0101-xxAduhelm 170 mg/1.7 mL (100 mg/mL) solution in a SDV NDC (package)
    64406-0102-xxAduhelm 300 mg/3 mL (100 mg/mL) solution in a SDV NDC (package)
    Covered Diagnosis Codes / Medicare Part B relevant codesICD-10
    G30.0Alzheimer's disease with early onset
    G30.1Alzheimer's disease with late onset
    G30.9Alzheimer's disease, unspecified
    G31.84Mild cognitive impairment, so stated

    Provider Requirements and Impact

    Prior Authorization

    Prior authorization required for Aduhelm

    Prior authorization is required for Aduhelm (aducanumab-avwa).

    Step Therapy

    No step therapy — investigational designation

    No step therapy pathways are specified; the policy designates Aduhelm investigational for all indications.

    Billing Rule

    Prior authorization, billing codes, and diagnosis documentation

    Submit a prior authorization request for Aduhelm and bill using HCPCS code J0172 (Injection, aducanumab-avwa, 2 mg; 1 billable unit = 2 mg). Use the listed NDCs for vial sizes: 64406-0101-xx (170 mg/1.7 mL) and 64406-0102-xx (300 mg/3 mL). Diagnosis coding should align with Appendix 1 (examples: G30.0, G30.1, G30.9, G31.84).

    • Prior authorization: Aduhelm must have prior authorization before administration.
    • Billing HCPCS: J0172 — Injection, aducanumab-avwa, 2 mg (1 billable unit = 2 mg).
    • NDCs: 64406-0101-xx (170 mg/1.7 mL), 64406-0102-xx (300 mg/3 mL).
    • Diagnosis codes: follow Appendix 1 (e.g., G30.0, G30.1, G30.9, G31.84).
    Denial Risk

    Investigational — denial risk for all indications

    Requests for Aduhelm will be denied as investigational for all indications, including treatment of Alzheimer's disease and cognitive impairment due to AD.

    Clinical Background

    Aduhelm (aducanumab-avwa) is a monoclonal antibody therapy that targets aggregated forms of amyloid-beta in the brain. It was evaluated for use in Alzheimer's disease because accumulation of amyloid-beta plaques is a central pathological feature of AD; however, clinical trials have not provided consistent evidence of meaningful clinical benefit, and the policy therefore considers the treatment investigational.

    Definitions

    Aduhelm (aducanumab-avwa) — definition and brief drug description
    Generic nameAduhelm (aducanumab-avwa)
    Drug classRecombinant human IgG1 monoclonal antibody
    Target / mechanismDirected against aggregated soluble and insoluble forms of amyloid‑beta; promotes clearance of beta‑amyloid plaques from the brain
    Route of administrationIntravenous infusion
    Accelerated approval — definition as it pertains to Aduhelm
    DefinitionFDA accelerated approval: a pathway intended to expedite drugs to market using surrogate evidence when measuring actual clinical endpoints would take too long.
    Application to AduhelmAduhelm was granted accelerated approval by the FDA on June 7, 2021 based on evidence of beta‑amyloid plaque reduction as a surrogate endpoint.
    Confirmatory requirementAccelerated approval typically requires subsequent confirmatory trials to verify clinical benefit; Aduhelm had subsequent confirmatory trials (ENGAGE and EMERGE) with mixed results.
    Regulatory contextAccelerated approval may be used in rare situations where preferred measurement of clinical endpoints would take too long; FDA advisory committee had concerns about clinical data for aducanumab prior to approval.
    Policy Summary
    PayerCapital Bluecross
    PolicyAduhelm (aducanumab-avwa) (Intravenous) Coverage Criteria
    Policy CodePolicy IC-0610NC
    Change TypeNo material change
    Effective Date
    Last ReviewJun 1, 2023
    Next Review DateJun 1, 2023
    Key ActionObtain prior authorization for Aduhelm (aducanumab-avwa) before billing.
    SourceLink
    On This Page
    Coverage DeterminationBilling and Diagnosis CodesProvider Requirements and ImpactClinical BackgroundDefinitions